Pankreas Hastalıklarında Güncel Gelişmeler

Shore ER, Awais M, Kershaw NM et al. Small molecule inhibitors of cyclophilin D to protect mitochondrial function as a potential treatment for acute pancreatitis. J. Med. Chem. 2016; 59: 2596–611.
Zhu Y, Pan X, Zeng H, et al. A study on the etiology, severity, and mortality of 3260 patients with acute pancreatitis according to the revised atlanta classification in Jiangxi, China over an 8-year period. Pancreas 2017;46:504–9.
Moggia E, Koti R, Belgaumkar AP, et al. Pharmacological interventions for acute pancreatitis. Cochrane Database Syst Rev 2017;4:CD011384.
Huang W, Cane MC, Mukherjee R, et al. Caffeine protects against experimental acute pancreatitis by inhibition of inositol 1,4,5-trisphosphate receptor-mediated Ca2+ release. Gut 2017;66(2):301–13.
Carr RA, Rejowski BJ, Cote GA, et al.: Systematic review of hypertriglyceridemia-induced acute pancreatitis: A more virulent etiology? Pancreatology. 2016; 16(4): 469–76.
Nawaz H, Koutroumpakis E, Easler J, et al.: Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015; 110(10): 1497–503.
Banks PA, Bollen TL, Dervenis C, et al.: Classification of acute pancreatitis-- 2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013; 62(1): 102–11.
De Lisi S, Leandro G, Buscarini E: Endoscopic ultrasonography versus endoscopic retrograde cholangiopancreatography in acute biliary pancreatitis: a systematic review. Eur J Gastroenterol Hepatol. 2011; 23(5): 367–74.
Vege SS, DiMagno MJ, Forsmark CE, et al.: Initial Medical Treatment of Acute Pancreatitis: American Gastroenterological Association Institute Technical Review. Gastroenterology. 2018; 154(4): 1103–39.
Buxbaum JL, Quezada M, Da B, et al.: Early Aggressive Hydration Hastens Clinical Improvement in Mild Acute Pancreatitis. Am J Gastroenterol. 2017; 112(5): 797–803.
Crockett SD, Wani S, Gardner TB, et al.: American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology. 2018; 154(4): 1096–101.
Besselink MG, van Santvoort HC, Buskens E, et al.: Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebocontrolled trial. Lancet. 2008; 371(9613): 651–9.
Tse F, Yuan Y: Early routine endoscopic retrograde cholangiopancreatography strategy versus early conservative management strategy in acute gallstone pancreatitis. Cochrane Database Syst Rev. 2012; (5): CD009779.
da Costa DW, Bouwense SA, Schepers NJ, et al.: Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. Lancet. 2015; 386(10000): 1261–8.
Mandalia A, Wamsteker EJ, DiMagno MJ. Recent advances in understanding and managing acute pancreatitis. F1000Res. 2018;7:F1000 Faculty Rev-959. Published 2018 Jun 28.
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377(1):62–70.
Sankaran SJ, Xiao AY, Wu LM, Windsor JA, Forsmark CE, Petrov MS. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis. Gastroenterology 2015;149:1490-1500.
Forsmark CE. Management of chronic pancreatitis. Gastroenterology 2013;144:1282-1291.
Abu-El-Haija M, Conwell DL. Pancreatic Insufficiency: What Is the Gold Standard? Gastrointest Endosc Clin N Am 2018;28:521-528.
Kwon CI, Kim HJ, Korc P, et al. Can we detect chronic pancreatitis with low serum pancreatic enzyme levels? Pancreas 2016;45:1184-1188.
Oh HC, Kwon CI, El Hajj II, et al. Low serum pancreatic amylase and lipase values are simple and useful predictors to diagnose chronic pancreatitis. Gut Liver 2017;11:878-883.
Mensel B, Messner P, Mayerle J, et al. Secretin-stimulated MRCP in volunteers: assessment of safety, duct visualization, and pancreatic exocrine function. AJR Am J Roentgenol 2014;202:102-108.
Tirkes T, Fogel EL, Sherman S, et al. Detection of exocrine dysfunction by MRI in patients with early chronic pancreatitis. Abdom Radiol (NY) 2017;42:544-551.
Anaizi A, Hart PA, Conwell DL. Diagnosing chronic pancreatitis. Dig Dis Sci 2017;62:1713-1720.
Lohr JM, Dominguez-Munoz E, Rosendahl J, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J 2017;5:153- 199.
Cote GA, Slivka A, Tarnasky P, et al. Effect of covered metallic stents compared with plastic stents on benign biliary stricture resolution: a randomized clinical trial. JAMA 2016;315:1250-1257.
Ahmed Ali U, Pahlplatz JM, Nealon WH, van Goor H, Gooszen HG, Boermeester MA. Endoscopic or surgical intervention for painful obstructive chronic pancreatitis. Cochrane Database Syst Rev 2015:CD007884.
CDC (2021). Update on Cancer Deaths 2021. (20/11/2021 tarihinde https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm adresinden ulaşılmıştır).
Cancer Research (2021). Projecting Cancer Incidence and Deaths to 2030. (22/11/2021 tarihinde https://cancerres.aacrjournals.org/content/74/11/2913 adresinden ulaşılmıştır).
Walter, F.M.; Mills, K.; Mendonça, S.C.; Abel, G.A.; Basu, B.; Carroll, N.; Ballard, S.; Lancaster, J.; Hamilton, W.; Rubin, G.P.; et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): A prospective cohort study. Lancet Gastroenterol. Hepatol. 2016, 1, 298–306.
Mostafa, M.E.; Erbarut-Seven, I.; Pehlivanoglu, B.; Adsay, V. Pathologic classification of “pancreatic cancers”: Current concepts and challenges. Chin. Clin. Oncol. 2017, 6, 59.
Masiak-Segit, W.; Rawicz-Pruszy ´nski, K.; Skórzewska, M.; Polkowski, W.P. Surgical treatment of pancreatic cancer. Pol. J. Surg. 2018, 90, 45–53.
Soloff, E.V.; Zaheer, A.; Meier, J.; Zins, M.; Tamm, E.P. Staging of pancreatic cancer: Resectable, borderline resectable, and unresectable disease. Abdom. Radiol. 2017, 43, 301–313.
Giri, B.; Sethi, V.; Dudeja, V.; Banerjee, S.; Livingstone, A.; Saluja, A. Genetics of pancreatic cyst-cancer progression. Curr. Opin. Gastroenterol. 2017, 33, 404–410.
Winter, J.M.; Brody, J.R.; Abrams, R.A.; Lewis, N.L.; Yeo, C.J. Chapter 49: Cancer of the Pancreas. In DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 10th ed.; DeVita, V.T., Lawrence, T.S., Rosenberg, S.A., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2015.
NCCN (2021). National Comprehensive Cancer Network. (22/11/2021 tarihinde https://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=96 adresinden ulaşılmıştır).
Kleeff, J.; Korc, M.; Apte, M.; La Vecchia, C.; Johnson, C.D.; Biankin, A.V.; Neale, R.E.; Tempero, M.; Tuveson, D.A.; Hruban, R.H.; et al. Pancreatic cancer. Nat. Rev. Dis. Primers 2016, 2, 16022.
Kent, O.A. Increased mutant KRAS gene dosage drives pancreatic cancer progression: Evidence for wild-type KRAS as a tumor suppressor? Hepatobiliary Surg. Nutr. 2018, 7, 403–405.
Kamerkar, S.; LeBleu, V.S.; Sugimoto, H.; Yang, S.; Ruivo, C.F.; Melo, S.A.; Lee, J.J.; Kalluri, R. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nat. Cell Biol. 2017, 546, 498–503.
Drilon, A.; Laetsch, T.W.; Kummar, S.; Dubois, S.G.; Lassen, U.N.; Demetri, G.D.; Nathenson, M.; Doebele, R.C.; Farago, A.F.; Pappo, A.S.; et al. Efficacy of Larotrectinib inTRKFusion–Positive Cancers in Adults and Children. N. Engl. J. Med. 2018, 378, 731–739.
Pokataev, I.; Fedyanin, M.; Polyanskaya, E.; Popova, A.; Agafonova, J.; Menshikova, S.; Tryakin, A.; Rumyantsev, A.; Tjulandin, S. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: Comparative analysis of published clinical studies. ESMO Open 2020, 5, e000578.
Golan, T.D.; Kanji, Z.S.; Epelbaum, R.; Devaud, N.; Dagan, E.; Holter, S.; Aderka, D.; Paluchshimon, S.; Kaufman, B.A.; Gershonibaruch, R.; et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br. J. Cancer 2014, 111, 1132–1138.
Christenson, E.S.; Jaffee, E.; Azad, N.S. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: A bright future. Lancet Oncol. 2020, 21, e135–e145.
Alistar, A.; Morris, B.B.; Desnoyer, R.; Klepin, H.D.; Hosseinzadeh, K.; Clark, C.; Cameron, A.; Leyendecker, J.; D’Agostino, R.; Topaloglu, U.; et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: A single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017, 18, 770–778.
Rhim, A.D.; Oberstein, P.E.; Thomas, D.H.; Mirek, E.T.; Palermo, C.F.; Sastra, S.A.; Dekleva, E.N.; Saunders, T.; Becerra, C.P.; Tattersall, I.W.; et al. Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell 2014, 25, 735–747.